LONDON, June 10 /PRNewswire/ -- Premier Research Group plc, the international pharmaceutical services company, announces the completion of its previously announced management buyout. As a result, the company is no longer listed on the AIM market of the London Stock Exchange. The UK-based private equity firm ECI Partners provided funding for the transaction.
Said Dr. Simon Yaxley, Chief Executive Officer of Premier Research Group, “This event ensures that we are able to continue our thoughtful and measured ‘buy-and-build’ strategy to allow us to continue to deliver exceptional quality and service to our clients around the world.” Dr. Yaxley continued, “Further, we are pleased to announce that our existing management team remains fully intact, and is as dedicated as ever to ensuring our clients’ expectations are met or exceeded. As a result, our clients, both existing and prospective, will not experience any visible change in working with the Premier Research team.”
Mr. Richard Chapman of ECI Partners commented, “We are extremely pleased to have concluded this important transaction. We have long been interested in the CRO sector, and are excited to have found a successful and growing company such as Premier Research in which to invest. Our comprehensive due diligence confirmed our belief that Premier Research is a company of the highest quality with an exceptional future in providing clinical research services to global pharmaceutical, biotechnology, and medical device companies. We are also pleased that the existing management team remains committed to the long-term success of the business.”
About Premier Research
Premier Research is a leading solutions-driven CRO committed to therapeutic focus and operational expertise to deliver clinical trial services of the highest quality for biopharmaceutical and medical device companies. They are leaders in clinical research for Analgesia, CNS, Infectious Disease, and Oncology and have a wealth of experience in medical device and pediatric research.
Premier Research has 30 offices and operates in more than 30 countries across Europe and North America. Premier Research employs more than 1,200 clinical professionals dedicated first and foremost to fulfilling each client’s requirements in a timely, accurate and cost-effective manner. This includes a strong international network of monitors and project management professionals combined with regulatory, data management, statistical, scientific and medical experts, and staff at our well-established network of dedicated clinical sites.
CONTACT: Dr. Simon Yaxley, Chief Executive Officer of Premier Research
Group plc, +44 (0)118 965 4082
